Diamthazole

Summary

Diamthazole (CHEMBL1184360) is an approved small molecule (ATC D01AE17).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AE17
• Chemistry: 293.4 Da · C15H23N3OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1184360
Name	Diamthazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8708
ATC	D01AE17
Molecular formula	C15H23N3OS
Molecular weight	293.4
InChIKey	WGMYEOIMVYADRJ-UHFFFAOYSA-N

SMILES: CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C

IUPAC name: 6-[2-(diethylamino)ethoxy]-N,N-dimethyl-1,3-benzothiazol-2-amine

Also known as: Dimazol, Dimazole, SID29216167, SID144205400, DIAMTHAZOLE, MMV1646507

Parent form; salt/anhydrous children: CHEMBL346235, CHEMBL1509531

Patent coverage: 147 distinct patent families (499 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 445 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.85	Potency	1412	nM	CHEMBL_ACT_3626923

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).